This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drugdevelopment. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.
Given macro healthcare influences (eg, economic uncertainty, environmental changes) and the numerous available treatments for major diseases, drugdevelopers may need to reassess their therapeutic strategies. This has led drugdevelopers to unintentionally limit their potential within chosen therapeutic spaces.
Although it is currently only used in veterinary therapy, carprofen proves to be a molecule with a versatile therapeutic potential for human pharmacotherapy. Moreover, the molecule is a target in the drug discovery process for the development of new bioactive compounds.
Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.
link] Proteins labelled site-specifically with smallmolecules are valuable assets for chemical biology and drugdevelopment. Nat Commun 15 , 859 (2024). In addition to protein bioconjugation, the bis-heterocyclic scaffold we report herein will find applications in synthetic and medicinal chemistry.
Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in smallmoleculedrug discovery. Data sharing without compromise Drug discovery has long been characterised by a strong culture of secrecy.
Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional smallmoleculedrug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.
Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drugdevelopment lifecycle.
It is estimated that 70% to 80%1 of smallmoleculedrug candidates in development today can be classified as poorly water-soluble. Optimize Your DrugDevelopment Timeline With This Dosage Form Can you name five benefits of using liquid-filled, hard-shell capsules in drugdevelopment over other solid oral dosage forms?
Drugdevelopment is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates.
Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drugdevelopment world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve. Why does that matter?
Where data was publicly available, the routes of human metabolism for each of the drugs in this subset is listed in Table 1. Metabolites found in humans are also observed in monkeys, and all metabolites were found to possess <10% of the activity of the parent drug. of the administered radiolabel in the human ADME study.
In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drugdevelopers for phase I trials, second only to navigating regulatory compliance (- 38 percent).
The road to developing effective drugs is fraught with both promise and challenge, particularly when it comes to what scientists call "undruggable" targets. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.
Artificial Intelligence (AI) is poised to transform the field of target discovery in drugdevelopment, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. This means that we are not doing something right.
In the constantly evolving field of drug discovery, the term “undruggable” refers to proteins and targets in the body that, until recently, were considered impossible to treat with traditional drugs. This is a game-changer, especially in the fight against cancer and other complex diseases.
The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.
Unlike traditional pharmacokinetic (PK) studies that rely on plasma measurements alone, MSI, when combined with traditional histology, enables spatial mapping of drug distribution, metabolism and target engagement. Toxicological investigations play a key role in assessing drug safety and, importantly, inform development decisions.
Novel smallmoleculedrug candidates will target GPR75 to potentially address obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits. Yancopoulos, M.D.,
As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted smallmolecules aimed at revolutionising cancer treatment. This suited my personality and constant curiosity more than academic research.
Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development.
Enzymes involved in glucose metabolism may be promising therapeutic targets for drugdevelopment against the pathogenic free-living amoebae. Details about the enzyme sequence and structural properties make a compelling case for designing smallmolecule inhibitors that are specific to the amoebae and would not affect the host enzyme.
Engaging at the outset with a fully integrated and experienced drugdevelopment partner can ensure safety, with timely data sharing at every step of the drugdevelopment plan, and facilitate agile, flexible decision-making and planning.
While these approaches often produce encouraging initial results, the development of drug resistance remains a major obstacle for long-term patient survival. Classically, rational drug combinations are designed to target two nodes in the same oncogenic signalling pathway.
In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. A big part of the puzzle is selectivity—the ability of a drug to zero in on specific biological molecules without affecting others.
In this blog, we explain the role of clinical pharmacology in drugdevelopment and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways.
We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drugdevelopment process which promises to completely transform how we developdrugs with increases in productivity of an order of magnitude or more.
Combining Broad’s expertise in cancer biology and state-of-the-art drug discovery methods with Bayer’s expertise in drugdevelopment greatly increases our power to bring transformative medicines to cancer patients.” “We Through this alliance, Broad and Bayer have done just that.
Five Promising Treatment Areas in Early-Phase DrugDevelopment in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drugdevelopment is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.
Both the cost and the time required for each new drug approval have increased exponentially for decades (aptly tagged ‘Eroom’s Law’, being the inverse of price drops and speed gains in the semiconductor industry). There is, of course, no evidence of whether the claims made for AI in discovery and development are hype or reality.
Now comes word of another absolutely incredible use of cryo-EM: determining with great ease and exquisite precision the structure of the smaller organic chemical compounds, or “smallmolecules,” that play such key roles in biological exploration and drugdevelopment. Also analyzed were eight less-familiar smallmolecules.
Smallmolecule GLP1s? Whether trial design, execution, or otherwise, drugdevelopment even where there is precedent is a challenging road and should not be taken for granted. Whether it’s smallmolecules to target the incretins (GLP1R ± GIPR), targeting well-validated signaling nodes in I&I (e.g.,
To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. 6 In all these examples, an effective backbone drug was first developed, before adding one or more drugs to establish the new regimens.
In the case of urgent or immediate public interest, process validation may be conducted concurrently with manufacturing the commercial smallmolecule or biologic product to expedite product availability for patients. It ensures that a production process consistently yields products of predetermined quality and safety.
Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.
Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drugdevelopment and facilitating faster access to new therapies.
.–( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class smallmolecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Strovel, PhD, Chief Executive Officer of Veralox Therapeutics. About VLX-1005.
SPEAK WITH AN EXPERT Related resources you may be interested in: Webpage: Preclinical Research Solutions Scientific Journal: Planning Your Preclinical Assessment eBook: Altasciences Proactive DrugDevelopment Solution for SmallMolecules eBook: Altasciences Proactive DrugDevelopment Solution for Large Molecules Image Nonclinical_Safety_Testing_Guide_audiobook.jpg (..)
Drug discovery is always evolving. From new processes to advanced technologies, excellence in drug discovery is the result of combining different approaches. Emerging and Resurrecting Technologies We’ve made huge strides in the drug discovery process, and it’s only getting better as we move forward.
Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme.
As a small biotech company with new technology at the frontier of the known drug discovery universe, it may feel like you’re charting a course alone in a dark, cold, and empty void with hailing frequencies open, but with no incoming transmissions. But you would be wrong. This latter course is Arrakis’ strategy.
Micro- and macroalgae from both marine and fresh water produce smallmolecules and secondary metabolites with aggregative, anti-inflammatory, antioxidant, antimicrobial, anti-viral and anti-tumoural bioactivities. Examples include phlorotannins from brown seaweeds and smallmolecules like terpenoids and peptides, found in microalgae.
How have advancements in antibody-drug conjugates (ADCs) expanded treatment options for different types of cancer? The advent of monoclonal antibodies paired with improvements in each ADC design component has led to the approval of 11 ADCs with more than 180 ADCs currently in clinical development.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content